News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biothera Further Elucidates The Mechanism Of Action Of Cancer Immunotherapy Imprime PGG


1/30/2014 9:15:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EAGAN, Minn.--(BUSINESS WIRE)--Imprime PGG®, the phase 3 cancer immunotherapy drug from Biothera, utilizes distinct receptors and signaling pathways in monocytes to induce cytotoxic function. The research was published in the latest issue of Glycobiology.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Biothera
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES